Serratus平面阻滞(SPB)与辣椒症与肉毒杆菌A的慢性神经性疼痛 (SERCABOT)
The goal of this phase II clinical trial is to study the effectiveness of a treatment with Serratus Plane Block (SPB) or Botox-A in comparison with capsaicin for the control of chronic neuropathic pain of post-mastectomy syndrom, that is not adequately managed by systemic treatment alone. The primary outcome will be the pain evaluation at 8 weeks.
123 patients with chronic neuropathic pain of post-mastectomy syndrom insufficiently relieved by systemic treatment alone will be recruited over 24 months at the Centre Oscar Lambret.
Patients will be randomly assigned to one of three treatment groups (41 patients per group):
Capsaicin Botulinum toxin A SPB
Patients will be followed for 24 weeks after the study treatment. The follow-up will include remote evaluation and 2 medical visits during which pain and quality of life will be assessed.
研究概览
详细说明
SerCaBot is a randomized, open-label, phase II clinical trial designed to evaluate the efficacy of a treatment with Serratus Plane Block (SPB) or Botox-A compared to capsaicin for the control of chronic neuropathic pain of post-mastectomy syndrom, that is not adequately managed by systemic treatment alone.
123 patients with will be recruited over 24 months at the Centre Oscar Lambret.
This clinical trial will be proposed to patients with chronic neuropathic pain of post-mastectomy syndrome that is not adequately managed by systemic treatment alone.
After consent, an inclusion assessment will be carried out including clinical examination, anamnesis, pain assessment (questionnaires PCS, NPS, DN4, NPSI and collect of antalgic treatment) and evaluation of quality of life (questionnaire SF12) and depression (questionnaire HADS).
Patients will then be randomly assigned to one of three treatment groups : Capsaicin, Botox-A, SPB (41 patients per group). The randomization will be balanced 1:1:1, controlled by minimisation (with a random factor set at 0.8) for the distribution of the following factors:
- Pain level at enrolment (continuous NPS)
- Axillary dissection (yes vs. no)
- Loco-regional adjuvant radiotherapy (yes vs. no)
- Prior change of systemic treatment (yes vs. no)
The study treatment will be administered 1 to 2 weeks after randomization. Treatment will be stopped prematurely in the event of unacceptable toxicity or complication. In each group, a repeat of the treatment may be considered after 12 weeks if further pain control is required. In the SPB group, a repeat is also possible every 2 weeks.
Patients will be followed for 24 weeks after the study treatment. Follow-up will include:
- 2 medical visits at 8 weeks and at 24 weeks including pain assessment (questionnaires NPS, NPSI, record of antalgic treatment), record of adverse events related to study treatment and assessment of quality of life (SF12 questionnaire) and depression (questionnaire HADS).
- remote assessment at week-1, week-2, week-4 and week-6 including assessment of pain (questionnaires NPS, NPSI, record of antalgic treatment) and record of adverse events. This remote assessment will be repeated in case of repetition of treatment at week 12.
Patients will withdraw from the study after the 24 week medical visit. Early withdrawal will be possible in case of patient's decision of withdrawal, breast surgery during follow-up, or death.
研究类型
阶段
- 阶段2
联系人和位置
学习地点
-
-
Hauts-de-France
-
Lille、Hauts-de-France、法国、59000
- Centre Oscar Lambret
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria :
-
Women aged ≥ 18 years;
-
Unilateral breast cancer treated by total or partial mastectomy:
- with sentinel lymph node technique (SLN) or axillary dissection;
- with or without immediate reconstruction using a prosthesis;
- associated or not with radiotherapy and/or chemotherapy;
-
Presenting moderate to severe chronic neuropathic pain, defined by:
- Numerical Pain Scale (NPS) ≥ 3 and DN4 ≥ 4,
- on a localised aera ((≤ 240 cm²), at the surgical site, in the axillary hollow, or on the inner side of the ipsilateral arm,
- between 3 and 9 months after breast surgery,
- with indication of additional locoregional treatment in complement to a systemic treatment of chronic neuropathic pain, as recommended by the SFETD - French Society for the Study and Treatment of Pain (tricyclic antidepressants or IRSNA or gabapentinoid PLUS lidocaine patch, at the appropriate dosage) and implemented for at least 4 weeks;
-
Patient affiliated with a health insurance plan;
-
Patient informed and having consented to participate in the trial.
Exclusion Criteria :
-
Ipsilateral breast cancer recurrence, regardless of the first treatment;
-
History of breast or thoracic surgery prior to mastectomy with residual pain;
-
Painful polyneuropathy related to chemotherapy requiring treatment;
-
Ongoing or planned loco-regional adjuvant radiotherapy within the next 8 weeks;
-
Treatment area not suitable for potential botulinum toxin type A treatment;
-
Breast reconstruction using flap or lipomodelling;
-
Indication for breast reconstruction within the next 8 weeks;
-
Chronic pain of another etiology such as:
- Neuropathic pain secondary to a neuroma (localized pain),
- Radiodermatitis,
- Phantom breast pain,
- Lymphedema,
- Complex regional pain syndrome,
- Adhesive capsulitis,
- Fibromyalgia;
-
Hypersensitivity or allergy to anesthetics, capsaicin, naropein, clonidine hydrochloride, an amide-type local anesthetic, botulinum toxin type A, or any excipient contained in the preparations;
-
Infection or inflammation at the injection site;
-
Therapeutic/effective anticoagulation;
-
Clinical signs or medical history leading to the diagnosis of:
- Hemostasis disorder,
- Local infection,
- Severe renal insufficiency (creatinine clearance < 30 mL/min),
- Thrombocytopenia < 50,000 platelets/mm3;
-
Generalized muscle activity disorders (e.g., myasthenia, Lambert-Eaton syndrome);
-
Heart rate lower than 60/minute;
-
Severe bradyarrhythmia due to sick sinus syndrome or second or third-degree atrioventricular block;
-
State of depression (HADS score ≥ 11);
-
Other contraindication to any of the study treatments;
-
Inability for the patient to follow the study schedule;
-
Inability for the patient or the healthcare team to perform the treatment within 2 weeks;
-
Pregnant or breastfeeding women, women who are able to conceive and who do not use a highly effective method of contraception during the trial and for at least 1 month after the end of treatment ;
-
Patient under guardianship or curatorship.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Capsaicin 8% Patch (Control)
Participants in this arm will receive an 8% capsaicin patch in a single treatment session in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks. |
One or two capsaicin patch (8%) are applied for 60 minutes to the site of neuropathic pain, in day-hospital. An oral, antalgic pre-medication may be done with one of the following medications (alone or association): paracetamol 1g, nefopam 30 mg, tramadol 100 mg, morphine 10mg, oxycodone 5mg. Capsaicin will be administered in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks.
其他名称:
|
|
实验性的:Serratus Plane Block (SPB)
Participants in this arm will undergo a Serratus Plane Block (SPB), a local anesthetic injection administered by a trained anesthesiologist, in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB can be repeated every two weeks up to a maximum of four sessions within the initial 8-week period if pain persists. A repeat treatment may be considered at 12 weeks if further pain control is needed. This intervention aims to provide extended pain relief for neuropathic pain in post-mastectomy patients |
The Serratus Plane Block (SPB) is a nerve block performed by a trained anesthesiologist to provide localized pain relief. It involves the injection of a local anesthetic: Maximum 150 mg naropeine combined with 150 μg clonidine hydrochloride into the serratus anterior plane under ultrasound guidance. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation.The SBP will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB may be repeated every two weeks up to four times in the initial 8-week period, with an additional repeat at 12 weeks if pain control remains insufficient.
其他名称:
|
|
实验性的:Botulinum Toxin A (Botox-A) Injection
This arm involves administration of Botulinum Toxin A (Botox-A) at the site of pain, in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain remains unresolved, the injection may be repeated at 12 weeks. Botox-A is used here as a local, long-lasting analgesic intervention aimed at reducing chronic neuropathic pain in patients post-mastectomy. |
Botulinum Toxin A (Botox-A) is injected into the affected area, with a total of 300 units administered across up to 60 injection sites. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation. This intervention will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks, and is aimed at providing prolonged pain relief for post-mastectomy neuropathic pain. Light sedation is provided, and injections may be repeated at 12 weeks if necessary.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pain assessment using Numerical Pain Scale (END)
大体时间:8 weeks after treatment initiation, or the closest measurement within +/- 1 week if the 8-week data is missing.
|
The primary outcome measure is pain assessed by self-evaluation using the Numerical Pain Scale (END) ranging from 0 (no pain) to 10 (worst pain imaginable) at rest, evaluated 8 weeks after treatment (or 9 weeks after randomization if treatment was not performed). The patient's self-assessment reflects individual treatment efficacy. In case of treatment interruption due to immediate intolerance or technical issues, the baseline END will be considered for the primary analysis. |
8 weeks after treatment initiation, or the closest measurement within +/- 1 week if the 8-week data is missing.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Success of Pain Control
大体时间:Assessed at 8 weeks post-treatment.
|
Defined as a reduction in pain of 3 points or more on the Numerical Pain Scale (END) at 8 weeks, with failure indicated in other cases. |
Assessed at 8 weeks post-treatment.
|
|
Evolution of Pain Scores
大体时间:Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
|
Change in pain levels as self-reported by the patient using the END at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated at 12 weeks). |
Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
|
|
Neuropathic Component Evaluation
大体时间:Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
|
Change in neuropathic symptoms assessed via the Neuropathic Pain Symptom Inventory (NPSI) at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated at 12 weeks). |
Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
|
|
Early Treatment Failure
大体时间:Assessed at 7 and 14 days post-treatment
|
Early failure of local analgesic treatment defined by failure to perform the procedure (due to intolerance or technical issues) or failure to control pain as evaluated at 7 and 14 days post-procedure. |
Assessed at 7 and 14 days post-treatment
|
|
Modification of introduction of New Analgesic Treatment
大体时间:Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
|
Documentation of any change in systemic treatement or introduction of new analgesic treatments (e.g., antiepileptics, antidepressants, opioids), with dosages collected at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated). |
Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
|
|
Adverse Events
大体时间:From study treatment to 24-weeks follow-up
|
Monitoring of adverse events possibly related to the treatment (capsaicin, botulinum toxin type A, or SBP block) during and after the local procedure, graded according to NCI-CTCAE v5.0. |
From study treatment to 24-weeks follow-up
|
|
HADS Scale Evaluation
大体时间:Assessed at baseline, 8 weeks, and 24 weeks.
|
Assessment of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS) at baseline, 8 weeks, and 24 weeks. |
Assessed at baseline, 8 weeks, and 24 weeks.
|
|
Quality of Life Assessment
大体时间:Assessed at baseline, 8 weeks, and 24 weeks.
|
Evaluation of health-related quality of life using the SF12 scale at baseline, 8 weeks, and 24 weeks. |
Assessed at baseline, 8 weeks, and 24 weeks.
|
|
Patient General Impression of Change (PGIC)
大体时间:Assessed at 8 weeks and 24 weeks
|
Self-assessment of change in condition from 1 (no change or worse) to 7 (considerable improvement) measured at 8 weeks and 24 weeks. |
Assessed at 8 weeks and 24 weeks
|
合作者和调查者
调查人员
- 首席研究员:Didier DELBROUCK, Anesthesiologist、Centre Oscar Lambret
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- SERCABOT-2302
- 2024-517420-20-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.